Breztri Triple Inhaler Gains EU Asthma Approval
Quick Facts
How Does Breztri Triple Therapy Treat Asthma?
Breztri combines budesonide, an inhaled corticosteroid that suppresses airway inflammation; glycopyrronium, a long-acting muscarinic antagonist; and formoterol, a long-acting beta2-agonist. This ICS/LAMA/LABA combination is intended to improve ongoing asthma control when an inhaled corticosteroid and long-acting beta2-agonist do not provide adequate control.
The two bronchodilators relax airway smooth muscle through separate biological pathways, while budesonide treats the underlying inflammation associated with asthma. The treatment is taken regularly as maintenance therapy. Patients should follow the authorized product instructions and retain the reliever medication recommended in their personal asthma action plan.
Who May Benefit From a Single-Inhaler Triple Treatment?
Before escalating treatment, clinicians generally reassess the diagnosis, symptom pattern, inhaler technique, adherence, environmental exposures and other conditions that can worsen asthma. International asthma guidance recommends addressing these factors because poor technique or inconsistent use can make an effective medicine appear inadequate.
A single inhaler may simplify delivery of three maintenance medicines, although it does not guarantee better adherence. Treatment should be individualized according to the approved European indication, previous therapy, exacerbation history and potential adverse effects. The European Commission decision does not itself authorize the same asthma indication in countries outside the European Union.
What Safety Issues Matter With Breztri?
Inhaled budesonide can cause oral candidiasis and hoarseness, so patients are commonly advised to rinse their mouth after use. Glycopyrronium may cause dry mouth and warrants caution in people with urinary retention or narrow-angle glaucoma, while formoterol can produce tremor, palpitations or other cardiovascular effects in some patients.
Sudden or rapidly worsening breathlessness requires the prescribed fast-acting reliever and, when severe or unresponsive, urgent medical care. Patients should not stop corticosteroid-containing treatment abruptly or change inhalers without clinical advice. Pharmacists and respiratory teams can help confirm correct device technique and explain how maintenance and rescue medicines differ.
Frequently Asked Questions
No. It is a maintenance inhaler and is not a substitute for the fast-acting reliever prescribed for sudden symptoms. Severe breathlessness, difficulty speaking or symptoms that do not respond to rescue treatment require urgent medical assessment.
No. Triple therapy is intended for selected patients who remain inadequately controlled despite appropriate treatment. A clinician should first review the diagnosis, adherence, inhaler technique, triggers, previous exacerbations and the authorized local indication.
No. European Commission authorization applies within the European Union. Medicine indications are reviewed separately by regulators in other jurisdictions, including the U.S. Food and Drug Administration.
References
- Fierce Pharma. Regulatory tracker: EC win marks 3rd asthma approval for AZ's Breztri. September 2026.
- European Medicines Agency. Trixeo Aerosphere: European public assessment report and product information.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention.